
25000 lipase units



This high lipase formulation of Creon should allow Cystic Fibrosis patients to substantially reduce their daily capsule intake and achieve better compliance.



HIGHER DOSE, FEWER CAPSULES, HAPPIER PATIENTS

Prescribing Information

Presentation: Opaque orange yellow hard gelatin capsules containing brownish coloured enteric coated pellets of pancreatin, equivalent to:

25,000 BP units of lipase

18,000 BP units of amylase

467 BP units of protease

Available in packs of 50. Basic NHS price £19.50

Indication: Pancreatic exocrine insufficiency

Dosage and Administration: Adults (including elderly) and children: Initially one capsule with meals, then adjust according to response.

The capsules can be swallowed whole, or for ease of administration they may be opened and the granules taken with fluid or soft food, but without chewing. If the granules are mixed with food it is important that they are taken immediately, otherwise dissolution of the enteric coating may result.

Contra-indications, Warnings, etc. Contra-indications: Substitution with pancreatic enzymes is contra-indicated in the early stages of acute pancreatitis. Warnings: Use in pregnancy: There is inadequate evidence of safety in use during pregnancy. The product is of porcine origin. Rarely cases of hyper-uricosuria and hyper-uricaemia have been reported with very high doses of pancreatin.

Overdosage although not experienced until now, could precipitate meconium ileus equivalent. Perianal irritation, and rarely, inflammation, could occur when large doses are used.

Product Licence Number: 5727 0006


Name and Address of Licence Holder

Kali Chemie Pharma GmbH, Hans-Bockler-Allee 20, 3000, Hannover 1, Germany. Further information is available from: Duphar Laboratories Limited, Gaters Hill, West End, Southampton SO3 3JD. Tel: (0703) 472281

® Registered Trade Mark

duphar
A member of the Solvay Group





One babymilk won't feed them all

but one babymilks company can.

Each baby has different needs which calls for a wide range of feeds.

Breastmilk is the best milk for a healthy baby so we advocate breastfeeding as a mother's first choice.

However, some babies need a low birth weight formula or a special dietary formula such as Nutrilon Soya previously Formula 'S', for milk intolerant infants. So you'll be relieved to hear that one company can respond to all these needs.


As specialists in infant nutrition Cow & Gate provide the widest range of feeds available today. For over 80 years it has been our business to make sure babies get the best. So you can rely on us to take care of them.



The Babyfeeding Specialists

Breastmilk is the best food for babies. The purpose of infant milk formula is to replace or supplement breastmilk when a mother cannot, or chooses not to, breastfeed. The cost of infant milk formula should be considered before deciding how to feed a baby.

This advertisement has been prepared for the information of the Health Care Professional only.



Prescribing Information Presentation: Epanutin Capsules, 25mg, 50mg, 100mg or 300mg phenytoin sodium Ph Eur. Epanutin Suspension 30mg/5ml phenytoin BP. Epanutin Infatabs, 50mg phenytoin BP. Indications: Grand mal epilepsy, temporal lobe seizures and certain other convulsive states. Dosage: Usual maintenance dosages: Infants and children: 4-8mg/kg, up to a maximum of 300mg daily. Adults: 200 -500mg daily in single or divided doses. Exceptionally, a daily dose outside this range may be indicated. Dosage recommendations are only guidelines and should be titrated for individual patients. Chew Infatabs. Titrate dosage gradually. Plasma level monitoring is advisable. Equal doses of Infatabs and capsules may not give equivalent blood levels. Contra-indications and precautions: Hypersensitivity to equivalent blood levels. Contra-indications and precautions: Hypersensitivity to hydantoins. Use in pregnancy and lactation. Liver dysfunction. Replacement of or with other anticonvulsant therapy should be gradual. Plasma levels may be altered by other drugs - see literature. Side-effects: Transient GI and CNS disturbances subsiding with continued use. Allergic phenomena (e.g. rash, lupus erythematosus, hepatitis, lymphadenopathy) may occur. Haematological disorders, gingival hypertrophy, hirsutism and excessive motor activity have been reported. Nystagmus with diplopia and ataxia indicates that dosage should be reduced. Legal category: POM. Product Licence Numbers: Capsules, 25, 50, 100mg/18/0112, 18/5079, 18/5080, 300mg, 18/0158. Suspension 18/5106. Infatabs 18/0069. Basic NHS cost: Capsules, 25mg 500 £9.82; 50mg 500 £10.02; 100mg 500 £12.77;1000 £24.15; 300mg 100 £7.66; Infatabs 100 £5.49. Suspension 500ml £3.56
Further information is available from Parke-Davis Research Laboratories,

Lambert Court, Chestnut Avenue, Eastleigh, Hampshire SO5 3ZQ. Telephone: (0703) 620500.

References

1. Data on file, Parke-Davis Research Laboratories.

PARKE-DAVIS DESERBITIONES

© Parke-Davis Research Laboratories 1992

* Trade mark

A118-UK-Mar92



Caring for nature's little things



WITH TAURINE

New formulation replaces Vamin® Infant

New Vaminolact® is formulated to closely resemble the natural source of protein for premature and older infants — human milk protein. So it's only natural that it should contain the right balance of essential and non-essential amino acids, like low phenylalanine and added taurine. New sulphite-free Vaminolact, specifically for use in paediatric parenteral regimens — when all that matters are the little things.

Kabi Pharmacia

FIRST LINE AMINO ACIDS FOR NEONATES AND INFANTS

ABBREVIATED PRESCRIBING INFORMATION

PRESENTATION: A solution for intravenous nutrition, specifically formulated for paediatric use.

L-Alanine	ხ.5§
L-Arginine	4.10
L-Aspartic acid	4.10
L-Cysteine/cystine	1.00
L-Glutamic acid	7.10
Glycine	2.10
L-Histidine	2.10
L-Isoleucine	3.10
L-Leucine	7.00
L-Lysine	5.60
L-Methionine	1.30
L-Phenylalanine	2.7g
L-Proline	5.60
L-Serine	3.80
Taurine	0.30
LThreonine	3.60
L-Tryptophan	1.40
L-Tyrosine	0.59
L-Valine	3.60
In each 1000ml	65.30
Osmolality: 510mosmol	per kg
water.	

Nitrogen per litre: 9.3g corre-

sponding to 58g of protein.

Energy content per litre: 240kcal

Indications: Vaminolact should be used for the prophylaxis and therapeutic treatment of protein depletion in neonates and infants where sufficient enteral nutrition is impossible or impracticable

Impossible or impracticable.

DOSAGE AND ADMINISTRATION:

Recommended dosage for Infants: the dosage should be increased gradually during the first week of administration to a final daily week or administration to a rinal daily dose of up to 35ml Vaminolact per kg body weight given as a continuous infusion over 24 hours. The duration of infusion should be at least 8 hours. Recommended dosage for **children:** The dosage should be increased gradually during the first week of administration to the final dosage ranges indicated below and should be infused over 24 hours:

Dosage* (mi
bodyweight
24 hours)
24.0
18.5
16.0
14.5

The duration of infusion should be at least 8 hours.

at least 8 nour.

Caution: The recommended infusion rate should not be exceeded.

Contra-indications, warnings etc: Vaminolact is contra-indicated in patients with irreversible liver damage and in severe uraemia when dialysis facilities are not available. Care must be exercised in the admini-

Care must be exercised in the administration of large volume infusion fluids to patients with cardiac insufficiency. Amino acid infusions must also be administered with caution to patients with disturbances in protein metabolism.

Precautions: Hyperkalaemia, hyperatraemia, and exidesis should be

natraemia, and acidosis should be corrected prior to commencement of intravenous nutrition. Serum electrolytes, blood glucose levels and acid-base balance should be regularly monitored. Fluid balance should also be monitored since hypertonic dehydration may occur. Amino acid solutions may precipitate acute folate deficiency and folic acid should be

Side-effects: Vaminolact is well tolerated. Rarely, nausea may occur.
As with all hypertonic solutions, thrombophlebitis may occur when peripheral veins are used. Abnormal liver function tests have been observed during intravenous

nutrition.

Legal category: POM.

Package quantities: Bottles of 100ml and 500ml.

Further information: The manu-

facturer can be consulted for full information on complete and balanced intravenous nutrition


Licence number:

Product authorisation numbers: 100ml 187/35/1. 500ml 187/35/2. Product Licence/Authorisation

Product Licence/Authorisation holder:
Kabi Pharmacia Limited, Davy Avenue, Knowihill, Milton Keynes, MK5 8PH. Distributed by Cahill May Roberts Limited for Kabi Pharmacia (Ireland), Pharmapark, Chapelizod, Dublin 20.
Cost: Vaminolact 100ml £3.80. Vaminolact 500ml £8.70.



per kg



Children with growth failure need the best care you can provide. And sometimes more.

The Lilly Growth Initiative is a new support programme aimed at everyone involved in the management of growth failure. The programme looks beyond the role of growth hormone therapy, to help create the right environment for growth.

It involves communicating with children at their own level, providing advice and reassurance in terms they can easily relate to. Helping parents to understand and deal with the challenges their children face. Offering practical assistance and material support to Growth Centres. Helping clinicians through educational support, growth data management, and information services.



Discover how the Lilly Growth Initiative can help you succeed in the management of growth failure. Write to: The Lilly Growth Initiative, Eli Lilly & Company Ltd., Dextra Court, Chapel Hill, Basingstoke, Hampshire RG21 2SY

The Lilly Growth Initiative. A growing involvement in child development.



European Journal of

Pediatrics

Incorporating
Acta Paediatrica Belgica
and
Helvetica Paediatrica Acta

Volume 151 No. 6 1992

The pioneers of pediatric medicine 397

Review

Flow cytometric immunophenotyping: principles and pitfalls M. Othmer, F. Zepp 398

Special article

International classification of osteochondrodysplasias

The International Working Group on Constitutional Diseases of Bone / Communicated by J. Spranger 407

Cardiology

Plasma endothelin concentration: relation with vascular resistance and comparison before and after balloon dilatation procedures
T. Ino, M. Ohkubo, S. Shimazaki,
K. Akimoto, K. Nishimoto, M. Iwahara,
K. Yabuta, Y. Hosoda
416

Enducrinology

Diabetes mellitus and exocrine pancreatic insufficiency in a girl with auto-immune haemolysis P. Sifianou, H. Tsoka, V. Kitra, S. Haidas, S. Pantelakis 420

The pattern of growth and growth retardation of patients with hypophosphataemic vitamin Dresistant rickets: a longitudinal study

R. Steendijk, R. C. Hauspie 422

Hematology/Oncology

Hypothalamic failure as a sequela of heterozygous protein C deficiency?

S. Schmitt, K. Auberger, T. Fendel, W. Kiess 428

Association of rib anomalies and malignancy in childhood R. Schumacher, A. Mai, P. Gutjahr 432

Immunology/Allergology

Cold haemagglutinin disease complicating *Mycoplasma* pneumoniae infection in a child under cytotoxic cancer treatment F. M. Fink, K. Dengg, S. Kilga-Nogler, D. Schönitzer, H. Berger 435

Iso-immune neonatal neutropenia due to an anti-Fc receptor III (CD16) antibody

J. Cartron, J. L. Celton, P. Gane, A. Astier, W. H. Fridman, G. Boissinot, J. P. Cartron **438**

Infectious diseases

Epidemiology of vertically transmitted HIV-1 infection in Switzerland: results of a nationwide prospective study

C. Kind, B. Brändle, C.-A. Wyler, A. Calame, C. Rudin, U. B. Schaad, J. Schüpbach, H.-P. Senn, L. Perrin, L. Matter, the Swiss Neonatal HIV Study Group 442

Medical genetics

Exomphalos, inguinal hernia, renal agenesis, skeletal dysplasia, heart disease – a "new" syndrome? G.Varlamis, K.Antoniades 449

Neonatology

Nosocomial bacterial infections in very low birth weight infants P. J. Thompson, A. Greenough, M. F. Hird, J. Philpott-Howard, H. R. Gamsu 451 Longitudinal assessment of infant lung function following pregnancies complicated by prolonged and preterm rupture of the membranes P. Thompson, A. Greenough, K. H. Nicolaides 455

The effects of mid-trimester amniocentesis on lung function in the neonatal period
A. D. Milner, E. W. Hoskyns, I. E. Hopkin 458

Evaluation by colour Doppler and pulsed Doppler sonography of blood flow velocities in intracranial arteries during the early neonatal period

T. Hayashi, T. Ichiyama, M. Uchida, N. Tashiro, H. Tanaka 461

Letters to the editors

Further evaluation of Vigabatrin therapy in 4-hydroxybutyric aciduria C.Jakobs, T.Michael, E.Jaeger, J.Jaeken, K.M.Gibson 466

Severe caffeine intoxication in a preterm neonate

J.N. van den Anker, H.T. M. Jongejan, P.J. J. Sauer 466

VACTERL plus hydrocephalus: a monogenic lethal condition J. Kunze, S. Huber-Schumacher, M. Vogel 467

Male triplets concordant for X-linked recessive nonsyndromic hypoparathyroidism A. S. Teebi, A. R. Kishawi, A. H. Malek 468

News for the practitioner 469

Indexed in Current Contents



Springer International

Subscription information


Volume 151 (12 issues) will appear in 1992. Information about obtaining back volumes and microform editions available upon request.

North America. Annual subscription rate: approx. US \$ 991.00 (single issue price approx. \$ 98.00), including carriage charges. Subscriptions are entered with prepayment only.

Orders should be addressed to: Springer-Verlag New York Inc. Service Center Secaucus 44 Hartz Way Secaucus, NJ 07094, USA Tel. (201) 348-4033 Telex 023125994 FAX (201) 348-4505

All other countries. Annual subscription rate: DM 1698.00 plus carriage charges; Federal Republic of Germany: DM 21.19 incl. value added tax; all other countries: DM 40.20 except for the following countries to which SAL delivery (Surface Airmail Lifted) is mandatory: Japan DM 105.00, India DM 76.20, Australia/ New Zealand DM 120.60. Airmail delivery to all other countries is available upon request. Volume price: DM 1698.00, single issue price: DM 169.80 plus carriage charges. Subscriptions can either be placed via a bookdealer or sent directly to:

Springer-Verlag Heidelberger Platz 3, 1000 Berlin 33, FRG Tel. (0)30/8207-0, Telex 183319 FAX (0)30/8214091



A world of difference

More and more patients with uncontrolled epilepsy are able to face the world thanks to the efficacy of SABRIL.

Many have become seizure free for the first time and approximately half can benefit from a > 50% reduction in their seizures.¹



Controlling seizures, changing lives

Abridged Prescr SABRIL Tablets

Presentation: White tablets with a breakline marked SABRIL, each containing 500mg vigabatrin

es: *Indications*: Treatment of epilepsy not controlled by other artiepileptic drugs. ese: *Indications*: Treatment of epilepsy not controlled by other artiepileptic drugs. esge and Administration: Oral administration once or twice daily added to the patient's current therapeutic regimen

Adults: Recommended starting dose 2g/day. Increased or decreased in 0.5g or 1.0g increments depending upon clinical response and tolerability. Maximum 4g/day. There is no direct correlation between plasma concentration and efficacy.

Children: The recommended starting dose in children is 40mg/kg/day increasing to 80-100mg/kg/day depending on response. Convenient recommendations in relation to bodyweight are:

10 - 15kg 15 - 30kg 30 - 50kg 0.5 to 1g/day 1.0-1.5g/day

30-50kg 1.5-3g/day
>50kg 2-4g/day
Infants with West syndrome may require doses of 100mg/kg/day or higher.

Elderly: Consider dose reduction in patients with impaired renal function.

Contra-Indications, Precautions, Warmings etc.

Use in pregnancy and lactation: Contra-indicated.

Precautions: Abrupt withdrawal may lead to rebound seizures. Caution in patients with history of psychosis or behavioural problems. Caution in elderly patients, particularly creatinine clearance below 60ml/min. Reduce dose and monitor closely for adverse events.

Warnings: Vigabatrin causes intramyelinic bedema in the brain white matter tracts of animals but there is no evidence of this in man. However, monitor patients for neurological changes. See the full

ects on driving ability: Drowsiness has been seen and patients should be warned.

Side effects: Are mainly CNS related. Aggression and psychosis have been reported and a previous history of psychosis or a behavioural problem appears to be a predisposing factor. Other reported events: drowsiness and fatigue, dizziness, nervousness, irritability, depression, headache and less commonly confusion, memory disturbance and vision complaints; also weight gain and minor gastrointestinal side-effects. Also in children excitation and agitation. Some patients may experience an increase in seizure frequency with vigabatrin, particularly those with myoclonic seizures. Tests have not revealed evidence of neurotoxicity in humans. Lab data do not indicate renal or hepatic toxicity. Decreases in SGOT and SGPT have been observed. Chronic treatment may lead to a slight

Drug Interactions: Are unlikely. A gradual reduction of about 20% in plasma phenytoin concentration has been observed.

No clinically significant interactions with carbamazepine, phenobarbitone or sodium valproate. **Legal Category:** POM

Package Quantities: Blister strips of 10 in cartons of 100.

Product Licence Number: PL 4425/0098

NHS Price: £46.00

Date of Preparation: January 1992.
You must refer to the full prescribing information before administering Sabril. Further information including full product data sheet is available from the Licence Holder: Marion Merrell Dow Ltd., Lakeside House, Stockley Park, Uxbridge, Middlesex. UB11 1BE.

1. Mumford JP.Br J Clin Pract 1988; 42 (Suppl 61): 7-9



MARION MERRELL DOW LTD.



Trademarks: Marion, Merrell, Dow, Sabril, SAB/AD/0492

BC OF

EDITED BY ROY MEADOW

"... can be highly recommended." Child care, health and development

"... provides all those involved in child protection with a comprehensive review of the medical consequences of child abuse.'

Nursing Times

"... praise for the book is unstinted." BM7

"... buy this [book] as an introduction, a revision or a teaching aid-it is worth it."

Family Practice

"... well illustrated, referenced and indexed and should become a standard teaching text." SAM7

UK £10.95; Abroad £13.00 (BMA members £9.95 or £12.00) including postage, by air abroad.

Please enclose payment with order or send full details of American Express, Mastercard or VISA credit card.

Available from: BRITISH MEDICAL JOURNAL, PO Box 295, London WC1H 9TE, major medical booksellers or the BMJ bookshop in BMA House.

BRITISH ACCIDENT & EMERGENCY TRAINEES ASSOCIATION

OXFORD PAEDIATRIC TRAUMA CONFERENCE

St. Hugh's College, Oxford 14th & 15th September 1992

Speakers & Topics include:

Advanced Life Support Courses **Epidemiology of Childhood Accidents** Paediatric Airway care & analgesia Research in Accident Prevention Accident Department design Pre Hospital care & transportation Head Injury Management Dealing with the death of a child Surgical Intervention in trauma Orthopaedic Intervention in trauma Burns & ITU management

Imaging the injured child Paediatrician's Role in trauma J Tepas (Jacksonville) S Levene (London)

P Oakley (Stoke) T Beattie (Aberdeen)

P Grout (Hull) W Ummenhofer (Basle) P May (Liverpool)

B Wright (Leeds) D Lloyd (Liverpool)

C Colton (Nottingham) J Settle (Wakefield)

L Abernathy (Liverpool) M Ward Platt (Newcastle)

The conference will be followed by the commencement of an

ADVANCED PAEDIATRIC LIFE SUPPORT COURSE

Organised by the British Paediatric A & E Group 15th-18th September 1992 (Course limited to 24 participants)

CONFERENCE FEE: £230

APLS COURSE FEE: £325

Accommodation available at St. Hugh's College

Further details & Registration forms from:

Mr M Williams FRCS 6 Huntsmans Way, Badsworth West Yorkshire WF9 1BE (Tel: 0977 648 641)

While you're trying to make it better, make it bearable.






Prescribing information: Uses Nausea and vomiting due to chemotherapy or radiotherapy. Dosage Emetogenic chemotherapy and radiotherapy: Either, 8mg i.v. as a slow injection immediately before treatment, or 8mg orally 1 to 2 hours before treatment, followed by 8mg orally twelve-hourly. To protect against delayed emesis, Zofran should be continued orally, 8mg twice daily for up to 5 days. Highly emetogenic chemotherapy: A single dose of 8mg i.v. as a slow injection immediately before chemotherapy, followed by 8mg orally twice daily for up to 5 days to protect against delayed emesis. The efficacy of Zofran over the first 24 hours of highly emetogenic chemotherapy may be enhanced by the addition of a single i.v. dose of 20mg dexomethasone immediately before treatment. Alternatively, higher doses of Zofran may be beneficial, up to 32mg depending on the severity of the emetogenic challenge. Children: A single i.v. dose of 5mg/m² immediately before chemotherapy, followed by 4mg orally twelve-hourly for up to 5 days. Elderly and patients with renal impairment: No afteration of dosage, dosing frequency or route of administration is required over 65 years or with renal impairment. Patients with hepatic impairment: In patients with moderate or severe hepatic impairment, a total daily dosage of 8mg should not be exceeded. Contra-

indications Hypersensitivity to components. Precautions Pregnancy or lactation. Side effects Headache, constipation, a warm or flushing sensation in the head or epigastrium. Occasional transient rises in aminotransferases. Rare, immediate hypersensitivity reactions (see data sheet). Presentations Zofran Injection ampoules containing 4mg andansetron in 2ml aqueous solution or 8mg andansetron in 4ml aqueous solution (Product licence number 0004/0375, 4mg x 5 ampoules £52-50, 8mg x 5 ampoules £75). Zofran 4mg Tablets each containing 4mg andansetron (Product licence number 0004/0376, 4mg x 30 tablets £187-50). Zofran 8mg Tablets each containing 8mg andansetron (Product licence number 0004/0377, 8mg x 10 tablets £90). Product licence holder Glaxo Operations U.K. Limited, Greenford, Middlesex UB6 OHE. Zofran is a Glaxo trade mark. Further information is available on request from: Glaxo Laboratories Limited, Stockley Park West, Uxbridge, Middlesex UB11 IBI. Tel: 081-990 9444





"Value judgments about food are being made all the time—they are nearly always subjective and usually wrong." A Stewart Truswell, Boden professor of human nutrition at the University of Sydney, separates fact from fallacy in the ABC of Nutrition. This fully revised and updated edition offers the general medical reader a refreshingly down to earth review of all aspects of nutrition—from anorexia to obesity, infant feeding to dietary guides for the elderly—and will be invaluable for doctors and other medical professionals wishing to advise patients about their eating habits.


Review of the first edition

"Truswell . . . has written *the* introductory textbook for students of nutrition at any level . . . All physicians, medical students, nurses, nursing students, dieticians, dietician students, and those interested in nutrition education should have a copy of this book."

American Journal of Clinical Nutrition

Second edition March 1992

Paperback • ISBN 0 7279 0315 2 • 120 pages UK £8.95; Abroad £10.50 (BMA members £8.45 or £10.00)



Healthy women with normal pregnancies need little formal care; those at risk of damage to their own or their baby's health need the best of scientific medicine. The aim of antenatal care is to distinguish between these two groups, giving those who need it the full range of diagnostic and therapeutic measures while avoiding unnecessary intervention in those whose pregnancy proceeds normally. In the ABC of Antenatal Care Geoffrey Chamberlain, professor and chairman of the department of obstetrics and gynaecology at St George's Hospital Medical School, London, outlines the practicalities of routine antenatal care and the management of the major medical problems that may arise. Originally published as a series of articles in the BMJ, this manual discusses with common sense and humour the background to current practice and indicates how it could be improved in the 1990s.

Chapters include

- Normal antenatal management
 Detection and management of congenital abnormalities
 Work in pregnancy
- Medical problems in pregnancy Preterm labour

January 1992

Paperback • ISBN 0 7279 0313 6 • 96 pages UK £9.95; Abroad £12.00 (BMA members £8.95 or £11.00)

ORDER FORM British Medical Journal, PO Box 295, London WC1H 9TE

Please send me the following books:

Qty	y Title		Amount	
Prices inch	ude postage, by air abroad	☐ Please send me a book catalogue	TOTAL £	
(print clearly)				
			POSTCODE	
Cheque e	enclosed (made payable t	o British Medical Journal) £	Membership No	o
Debit my	AMERICAN EXPRESS	S/VISA/MASTERCARD Card N	o	
Expiry da	ite	Signature		
BMJ books	s are also available from maj	or booksellers or the BMJ bookshop in BM	1A House. Book tokens	accepted (UK only).



TREE SAMPLE COPY

Journal of Medical Genetics

EDITOR: PETER S HARPER

North American Editor: P. Michael Conneally • Cytogenetics Editor: Patricia A. Jacobs

Molecular Genetics Editor: Kay E. Davies • Reviews Editor: Rodney Harris

JOURNAL OF MEDICAL GENETICS,

the first to be devoted specifically to medical genetics, is pleased to announce continuing developments, in response to the needs of readers and authors.

NEW FEATURES FOR 1992

- Half Price Personal Subscriptions for all Members of Major Societies, including European Society for Human Genetics, Clinical Genetics Society and The American Society of Human Genetics
- Change to A4 Format providing
 - Improved Illustration Quality
 - Faster Publication
- New Literature Update Section
- New Gene Mapping Review Series on Major Chromosomal Regions
- Colour Reproduction

The journal will continue to feature General Reviews, Syndrome of the Month, Conference Reports, Original Papers and Short Reports on all aspects of medical genetics.

RESEARCH AREAS OF SPECIAL EMPHASIS


- Molecular Genetics and its Clinical and Cytogenetic Applications
- Dysmorphology and the Delineation of New Syndromes
- Fundamental Aspects of Human Genetics
- Development of Clinical Genetic Services

1992 Subscription Rate: £148, \$250 (USA Only) Special Members Rates: £74, \$125 To Order Your Subscription or Sample Copy Please Complete the Order Form Below:

Order Form

JOURNAL OF MEDICAL GENETICS ISSN: 0022-2593 PUBLICATION: Monthly SUBSCRIPTION RATE: £148, USA ONLY: \$250 SPECIAL MEMBERS RATES: £74, \$125 Please tick	Card Number MasterCard users should add the numbers appearing above their name Explry date		
Please enter my subscription, start date	Signature		
Please send me a sample copy (Your signature is essential, especially when paying by credit card)			
Please send me Instructions to Authors	Name (Capitals)		
Please enter my half price subscription, start date			
☐I am a member of	Address		
☐ I enclose a cheque for			
(Payable to British Medical Journal)			
I wish to pay by credit card.			
American Express/Visa(Barclaycard)/Mastercard	Date		
(Delete as appropriate) SI			

Send orders to: BMJ Publishing Group, BMA House, Tavistock Square, London, WC1H 9JR, or BMJ Publishing Group, Box No 560B, Kennebunkport, Maine 04046 (Direct Orders Only)



NovoPen® II

Already a design award winner,1 NovoPen II has recently received even more attention to detail. The latest model incorporates an easy grip on the dosage dial and a smoother action on the locking ring a safety feature unique to NovoPen II. The stylish new appearance completes the latest design improvements making NovoPen II even better than before.

PenMix® Penfill® cartridges

Biphasic Isophane Insulin Injection, Human Insulin (pyr).

The first premixed insulin in a Penfill was PenMix 30/70 Penfill, in a ratio well suited to the majority of diabetics using premixed insulins.



The introduction of four additional mixtures makes PenMix® Penfill® the widest range of premixed insulins available in

cartridges, and means that even more diabetics could be using NovoPen II.



New NovoFine® needles

The new NovoFine needles for NovoPen II are very fine 28-gauge needles for a virtually painless injection.2

NovoPen® III
FOR MIXTURES TOO

NOVO NORDISK A/S Copenhagen, Denmark

Purther information is available from: NOVO NORDISK PHARMACEUTICALS LTD Novo Neglisk Licese, Brustfield Purk. Brighten Road, Pass Pottags, Crawley Ven Suse (USI) 987: Telephone (0093) 6/3595.